Annals of the Rheumatic Diseases, ‎0003-4967

Journal

Publications

  1. 2021
  2. Published
  3. 2020
  4. Published
  5. Published
  6. Published
  7. Published
  8. Accepted/In press

    Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis

    Lorraine Harper, Apr 2020, (Accepted/In press) In: Annals of the Rheumatic Diseases.

    Research output: Contribution to journalArticlepeer-review

  9. Published
  10. Accepted/In press
  11. Published

    Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care

    Raymond Oppong, , , , , , , Sue Jowett, , , , , , , & , Feb 2020, In: Annals of the Rheumatic Diseases. 79, 2, p. 276-284 9 p.

    Research output: Contribution to journalArticlepeer-review

  12. Published

    EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies

    Benjamin Fisher & 2 others, Simon Bowman & , Jan 2020, In: Annals of the Rheumatic Diseases. 79, 1, p. 3-18 16 p., 216114.

    Research output: Contribution to journalArticlepeer-review

  13. 2019
  14. Published

    Urine metabolic profile in rheumatoid arthritis development

    Stephen Young & , 27 Jun 2019, In: Annals of the Rheumatic Diseases. 78, Suppl 2, p. 2129-2130 2 p.

    Research output: Contribution to journalAbstractpeer-review

  15. Published

    2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

    Caroline Gordon, 29 Mar 2019, In: Annals of the Rheumatic Diseases. 78, 6, p. 736-745 10 p.

    Research output: Contribution to journalReview articlepeer-review

  16. Published
  17. Published
  18. Published

    Current challenges in the development of new treatments for lupus

    Caroline Gordon, , & , 12 Jan 2019, In: Annals of the Rheumatic Diseases. 78, 6, p. 729-735 7 p.

    Research output: Contribution to journalArticlepeer-review

  19. Published
  20. 2018
  21. Published
  22. E-pub ahead of print

    Targeting early changes in the synovial microenvironment: a new class of immunomodulatory therapy?

    Jennifer Marshall, , , , , Ilfita Sahbudin, , , , , , Karim Raza, Andrew Filer, Christopher Buckley, & , 14 Dec 2018, (E-pub ahead of print) In: Annals of the Rheumatic Diseases.

    Research output: Contribution to journalArticlepeer-review

  23. E-pub ahead of print

    Hexokinase 2 as a novel selective metabolic target for rheumatoid arthritis

    Adam Croft, , , , , , , Christopher Buckley, , , & , 30 Jul 2018, (E-pub ahead of print) In: Annals of the Rheumatic Diseases.

    Research output: Contribution to journalArticlepeer-review

  24. Published
Previous 1 2 3 4 5 6 7 8 9 Next